{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.2","upperLimit":"1.5","value":"1.3"},{"groupId":"OG001","lowerLimit":"1.4","upperLimit":"6.9","value":"2.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"20"}],"units":"Participants"}],"description":"From date of registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause. Patients last known to be alive and progression free are censored at date of last contact.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive trametinib PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Trametinib"},{"description":"Patients receive either A) leucovorin calcium IV over 2 hours and fluorouracil IV continuously over 46-48 hours on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity or B) capecitabine PO BID on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Chemotherapy"}],"paramType":"MEDIAN","populationDescription":"Eligible and analyzable patients.","reportingStatus":"POSTED","timeFrame":"Up to 2 years from registration","title":"Progression-free Survival","type":"SECONDARY","unitOfMeasure":"months"}